复发性/耐药性多发性骨髓瘤的基于Venetoclax的治疗组合:实践模式和二次细胞遗传异常对结果的影响

Abiola Bolarinwa1, Madhu Nagaraj1, Saurabh Zanwar1

  • 1Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Blood cancer journal
|April 4, 2025
PubMed
概括

威尼托克拉克斯在复发性/耐药性多发性骨髓瘤 (RRMM) 患者中表现出有效性,患有t 然而,在缺乏这种遗传标记物的患者中,它的有效性是有限的,特别是高风险细胞遗传学.

相关概念视频

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K